Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

01 December 2007

Biomarkers assays for T-lymphocyte activation and proliferation applied in a multicenter clinical trial of AEB071 in renal transplantation

J. M. Kovarik, K. Budde, J. Steiger, J. M. Grinyo, F. Straube, A. Groenewegen, A. Vitalit, J. Geissler, J. Klupp, M. J. Barten

Ann Transplant 2008; 13(1): 42-42 :: ID: 880209

Abstract

Background: AEB071 is a novel protein kinase C inhibitor that blocks the activation of T-lymphocytes.
Material/Methods: In a multicenter phase 2 trial, de novo kidney transplant recipients received AEB071 200 mg twice-daily with basiliximab, tacrolimus, and corticosteroids. We collected blood samples in a subset of 28 patients before transplantation and on day 8 posttransplantation to quantify biomarkers of T-lymphocyte activation and proliferation. The study sponsor provided analytical reagents and trained the site personnel. Within 16 hours of collection, heparinized blood was stimulated with PMA and anti-CD28 for T-cell activation and frozen. For T-cell proliferation, heparinized blood was stimulated with lectin followed by addition of 3H-thymidine and then frozen. Frozen samples were sent to the analyzing laboratory via a central collection agency. T-cell activation was quantified by flow cytometry to yield the percent T-cells double positive for IL2 and TNF (IL2+TNF+). T-cell proliferation was quantified by scintillation counting of thymidine uptake. Data are medians [interquartile range].
Results: Before transplantation, the percent IL2+TNF+ T-cells was 2.0 [0.5-5.9]%. This was reduced by 100% posttransplant to 0 [0-0.1]% (p=0.002). Thymidine uptake was 5.0 [2.9-14.7] cpm - 103 before transplantation. This was reduced by 84% posttransplant to 0.7 [0.4-1.4] cpm - 103 (p=0.003).
Conclusions: Despite the complexity of these assays, they were successfully implemented in the context of an international clinical trial. These biomarkers yielded individualized, quantitative evidence that T-cell activation and proliferation were inhibited by the immunosuppressive regimen and will contribute to the overall interpretation of the study results.

Keywords: resistant bacteria, T-Lymphocytes, Tacrolimus

Comments

In Press

06 May 2022 : Original article  

Phosphatidylethanol (PEth) for Monitoring Sobriety in Liver Transplant Candidates: Preliminary Results of D...

Ann Transplant In Press; DOI: 10.12659/AOT.936293  

Most Viewed Current Articles

26 Jan 2022 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

24 Jul 2020 : Review article  

Kidney Transplantation in the Times of COVID-19 – A Literature Review

DOI :10.12659/AOT.925755

Ann Transplant 2020; 25:e925755

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358